# Evaluation of the Pharmacokinetics and Safety of BLU-5937 in Healthy Adult Japanese and Caucasian Subjects

> **NCT06179537** · PHASE1 · COMPLETED · sponsor: **Bellus Health Inc. - a GSK company** · enrollment: 34 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BLU-5937

## Key facts

- **NCT ID:** NCT06179537
- **Lead sponsor:** Bellus Health Inc. - a GSK company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-06
- **Primary completion:** 2021-10-22
- **Final completion:** 2021-11-21
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2023-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06179537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06179537, "Evaluation of the Pharmacokinetics and Safety of BLU-5937 in Healthy Adult Japanese and Caucasian Subjects". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06179537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*